ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …

Abstract Purpose: Immune-related RECIST (irRECIST) were designed to capture atypical
responses seen with immunotherapy. We hypothesized that, in patients with metastatic clear …

PURPOSE To determine the value of tumor cell programmed death-ligand 1 (PD-L1)
expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive …

Purpose: We sought to validate levels of CD8+ tumor-infiltrating cells (TIC) expressing PD-1
but not TIM-3 and LAG-3 (IF biomarker; Pignon and colleagues, 2019) and to investigate …

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …

Importance Response patterns with immunotherapy may differ from those of other
treatments. This warrants further investigation because some patients may benefit from …

Background The phase 3 CheckMate 214 trial demonstrated higher response rates and
improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line …

Background Nivolumab is approved for patients with metastatic renal cell carcinoma
(mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in …

INTRODUCTION: Immune checkpoint inhibitors (ICI) have been approved for patients with
clear cell renal cell carcinoma (ccRCC), but not all patients benefit from ICI. One reason is …

5006 Background: Nivolumab (nivo) is FDA approved for pts with VEGFR TKI-resistant RCC
and the nivo+ ipilimumab (nivo/ipi) combination is FDA approved for treatment naïve pts with …